## What the February 19, 2026 disclosure *really* signaled (beyond the slide headlines) ### 1) Reimbursement is moving from “hope” to an operational revenue lever The most important non-obvious takeaway from the investor call materials is that management is now anchoring the business case to a **final CMS gapfill payment rate of $854** for both tests—i.e., a concrete reference point that can be used to underwrite unit economics, contracting, and expected reimbursement pathways. ["$854 final CMS payment rate"](0001079973-26-000239|1) Equally telling: the deck frames **Medicare coverage as “ongoing (final required step for Medicare)”** and explicitly points to building **out-of-network billing capability expected in Q2 2026**, which is often the “plumbing” investors don’t model until it appears in black-and-white disclosure. ["Medicare coverage process is ongoing"](0001079973-26-000239|1) ["expected in Q2 2026"](0001079973-26-000239|1) ### 2) The quiet pivot: internal CLIA lab = margin control + capacity control The deck doesn’t just claim efficiency—it discloses a **recently launched internal CLIA lab** designed to both **lower costs** and **increase testing capacity**, including a stated **initial lab COGS reduction of ~30%** (with “additional reduction expected with scale”). ["Internal CLIA Lab was Recently Launched"](0001079973-26-000239|1) ["Initial lab COGS reduction by ~30%"](0001079973-26-000239|1) Between the lines, this reads as a deliberate effort to de-risk the scale-up phase: owning lab throughput and cost structure is how diagnostics stories avoid getting trapped in “volume growth with no margin.” ["Space to increase infrastructure and automation to increase capacity"](0001079973-26-000239|1) ### 3) Clinical + economic evidence is being packaged for payer conversations (not just publications) Management highlights **economic outcomes** in a way that appears tailored to payer decision-making, including **Epi+Gen CHD cost savings per QALY “up to $42K”** and a separate modeled savings claim for PrecisionCHD in an initial-assessment use case. ["cost savings per quality adjusted life year (QALY)"](0001079973-26-000239|1) ["Up to $42K"](0001079973-26-000239|1) ["~$113M"](0001079973-26-000239|1) This matters because the 8‑K frames the investor call agenda as including **“recent clinical data”** and **“reimbursement progress”**—the pairing implies the company is actively trying to convert evidence into coverage and utilization, not merely “prove science.” ["Recent clinical data"](0001079973-26-000239|0) ["Reimbursement progress"](0001079973-26-000239|0) ### 4) TAM isn’t a slogan here—it’s explicitly tied to CMS pricing (a subtle credibility upgrade) Rather than presenting a generic market-size slide, the company discloses that its TAM math is **internally estimated by multiplying the CMS final gapfill rate by estimated eligible Americans**—and then it shows eligibility counts for each test (e.g., **146M** and **60M**) alongside the **$854** CMS rate. ["TAM was calculated by multiplying the CMS final gapfill rate"](0001079973-26-000239|1) ["146M estimated eligible Americans"](0001079973-26-000239|1) ["60 M estimated eligible Americans"](0001079973-26-000239|1) ["$854 final CMS payment rate"](0001079973-26-000239|1) Even if you haircut adoption heavily, tying TAM to an explicit reimbursement reference point typically signals management expects reimbursement to be central to commercialization—not an afterthought. ["Meaningful reimbursement milestones and progress"](0001079973-26-000239|1) ### 5) Early commercialization is being architected as a distribution system (providers + channels + international) The deck maps a practical U.S. commercialization mix—**employers/unions, providers/health systems, and channel partners**—and it illustrates a scalable remote/provider workflow (kits, shipping, lab processing, report delivery). ["Commercial Targets in the U.S."](0001079973-26-000239|1) ["A Highly Scalable Testing and Reporting Process"](0001079973-26-000239|1) Internationally, the company disclosed a partnership push in India with **Aimil Ltd** and **Dr. Lal PathLabs**, positioning this as “opportunistic global expansion through partnerships” and explicitly calling out diversification beyond the U.S. market. ["Announced Partnership in India with Aimil Ltd"](0001079973-26-000239|1) ["Dr. Lal PathLabs"](0001079973-26-000239|1) ["Opportunity to diversify revenue beyond the U.S. market"](0001079973-26-000239|1) ### 6) The “AI” angle: a platform narrative designed for repeatable product expansion The presentation repeatedly frames the company as an **AI-driven, multi-omics engine** with a “scalable foundation for sustained product expansion,” and it explicitly claims a **“strong and growing pipeline”** and a **diversified U.S. and international commercialization strategy**—language that’s less about a single-test story and more about building a durable product factory. ["AI - Dr iven Multi - Omics Engine"](0001079973-26-000239|1) ["scalable foundation for sustained product expansion"](0001079973-26-000239|1) ["Strong and growing pipeline"](0001079973-26-000239|1) ["Diversified US and international commercialization strategy"](0001079973-26-000239|1) --- **Bottom line (the “alpha”):** This disclosure reads like a company trying to transition from “innovation narrative” to **reimbursement-anchored execution**—with billing infrastructure timelines, internal cost control via a CLIA lab, and payer-ready economic framing that could matter more than the headline TAM if it drives real covered lives and repeat ordering. ["Establishing out - of - network billing capability (expected in Q2 2026)"](0001079973-26-000239|1) ["Initial lab COGS reduction by ~30%"](0001079973-26-000239|1) ["cost savings per quality adjusted life year (QALY)"](0001079973-26-000239|1)

## What the February 19, 2026 disclosure *really* signaled (beyond the slide headlines) ### 1) Reimbursement is moving from “hope” to an operational revenue lever The most important non-obvious takeaway from the investor call materials is that management is now anchoring the business case to a **final CMS gapfill payment rate of $854** for both tests—i.e., a concrete reference point that can be used to underwrite unit economics, contracting, and expected reimbursement pathways. ["$854 final CMS payment rate"](0001079973-26-000239|1) Equally telling: the deck frames **Medicare coverage as “ongoing (final required step for Medicare)”** and explicitly points to building **out-of-network billing capability expected in Q2 2026**, which is often the “plumbing” investors don’t model until it appears in black-and-white disclosure. ["Medicare coverage process is ongoing"](0001079973-26-000239|1) ["expected in Q2 2026"](0001079973-26-000239|1) ### 2) The quiet pivot: internal CLIA lab = margin control + capacity control The deck doesn’t just claim efficiency—it discloses a **recently launched internal CLIA lab** designed to both **lower costs** and **increase testing capacity**, including a stated **initial lab COGS reduction of ~30%** (with “additional reduction expected with scale”). ["Internal CLIA Lab was Recently Launched"](0001079973-26-000239|1) ["Initial lab COGS reduction by ~30%"](0001079973-26-000239|1) Between the lines, this reads as a deliberate effort to de-risk the scale-up phase: owning lab throughput and cost structure is how diagnostics stories avoid getting trapped in “volume growth with no margin.” ["Space to increase infrastructure and automation to increase capacity"](0001079973-26-000239|1) ### 3) Clinical + economic evidence is being packaged for payer conversations (not just publications) Management highlights **economic outcomes** in a way that appears tailored to payer decision-making, including **Epi+Gen CHD cost savings per QALY “up to $42K”** and a separate modeled savings claim for PrecisionCHD in an initial-assessment use case. ["cost savings per quality adjusted life year (QALY)"](0001079973-26-000239|1) ["Up to $42K"](0001079973-26-000239|1) ["~$113M"](0001079973-26-000239|1) This matters because the 8‑K frames the investor call agenda as including **“recent clinical data”** and **“reimbursement progress”**—the pairing implies the company is actively trying to convert evidence into coverage and utilization, not merely “prove science.” ["Recent clinical data"](0001079973-26-000239|0) ["Reimbursement progress"](0001079973-26-000239|0) ### 4) TAM isn’t a slogan here—it’s explicitly tied to CMS pricing (a subtle credibility upgrade) Rather than presenting a generic market-size slide, the company discloses that its TAM math is **internally estimated by multiplying the CMS final gapfill rate by estimated eligible Americans**—and then it shows eligibility counts for each test (e.g., **146M** and **60M**) alongside the **$854** CMS rate. ["TAM was calculated by multiplying the CMS final gapfill rate"](0001079973-26-000239|1) ["146M estimated eligible Americans"](0001079973-26-000239|1) ["60 M estimated eligible Americans"](0001079973-26-000239|1) ["$854 final CMS payment rate"](0001079973-26-000239|1) Even if you haircut adoption heavily, tying TAM to an explicit reimbursement reference point typically signals management expects reimbursement to be central to commercialization—not an afterthought. ["Meaningful reimbursement milestones and progress"](0001079973-26-000239|1) ### 5) Early commercialization is being architected as a distribution system (providers + channels + international) The deck maps a practical U.S. commercialization mix—**employers/unions, providers/health systems, and channel partners**—and it illustrates a scalable remote/provider workflow (kits, shipping, lab processing, report delivery). ["Commercial Targets in the U.S."](0001079973-26-000239|1) ["A Highly Scalable Testing and Reporting Process"](0001079973-26-000239|1) Internationally, the company disclosed a partnership push in India with **Aimil Ltd** and **Dr. Lal PathLabs**, positioning this as “opportunistic global expansion through partnerships” and explicitly calling out diversification beyond the U.S. market. ["Announced Partnership in India with Aimil Ltd"](0001079973-26-000239|1) ["Dr. Lal PathLabs"](0001079973-26-000239|1) ["Opportunity to diversify revenue beyond the U.S. market"](0001079973-26-000239|1) ### 6) The “AI” angle: a platform narrative designed for repeatable product expansion The presentation repeatedly frames the company as an **AI-driven, multi-omics engine** with a “scalable foundation for sustained product expansion,” and it explicitly claims a **“strong and growing pipeline”** and a **diversified U.S. and international commercialization strategy**—language that’s less about a single-test story and more about building a durable product factory. ["AI - Dr iven Multi - Omics Engine"](0001079973-26-000239|1) ["scalable foundation for sustained product expansion"](0001079973-26-000239|1) ["Strong and growing pipeline"](0001079973-26-000239|1) ["Diversified US and international commercialization strategy"](0001079973-26-000239|1) --- **Bottom line (the “alpha”):** This disclosure reads like a company trying to transition from “innovation narrative” to **reimbursement-anchored execution**—with billing infrastructure timelines, internal cost control via a CLIA lab, and payer-ready economic framing that could matter more than the headline TAM if it drives real covered lives and repeat ordering. ["Establishing out - of - network billing capability (expected in Q2 2026)"](0001079973-26-000239|1) ["Initial lab COGS reduction by ~30%"](0001079973-26-000239|1) ["cost savings per quality adjusted life year (QALY)"](0001079973-26-000239|1)